ArticleEndocrine oncology (Bristol, England)2026
Trends in metastatic thyroid cancer survival from 1992 to 2022: a SEER database analysis.
Article in Endocrine oncology (Bristol, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The majority of thyroid cancers present as localized disease that is treated with surgery or radioactive iodine. Despite the effectiveness of radioactive iodine, 5-10% of thyroid cancers are radioiodine-resistant and are termed radioiodine-refractory (RAIR) thyroid cancers. RAIR tumors that spread distantly exhibit high mortality. Phase III trials, in the early 2010s, for tyrosine kinase inhibitors (TKIs) such as lenvatinib, sorafenib, and cabozantinib have shown promise in extending progression-free survival (PFS) in patients with RAIR, but it remains unclear whether these advances have improved disease-specific survival (DSS). We conducted a survival analysis of metastatic thyroid cancers using the Surveillance, Epidemiology, and End Results (SEER) national database to assess changes in DSS from 1992 to 2022. Patients were divided into three cohorts based on the year of diagnosis: 1992-2001, 2002-2011, and 2012-2022. Kaplan-Meier and Cox regression analyses were used to assess survival trends and effects of demographic and treatment variables. Our results suggest a modest but significant improvement in DSS for those diagnosed with distant metastasis of anaplastic, follicular, medullary, and oncocytic thyroid carcinoma in the most recent decade (2012-2022) compared to earlier periods. Limited information on detailed treatment data, imposed by the use of SEER, ought to be considered. Future studies with more detailed treatment data would be beneficial for confirming our findings and better characterizing RAIR thyroid cancer survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.